Iron therapy in iron deficiency anemia in pregnancy: Intravenous route versus oral route

Bayoumeu, F.; Subiran-Buisset, Carole; Baka, Nour-Eddine; Legagneur, Henryse; Monnier‐Barbarino, Patricia; Laxenaire, M

doi:10.1016/s0301-2115(05)80402-6

Cited by 66 publications

(92 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these cases parenteral forms of iron administration are indicated. Bayoumeu et al (2002) 15 in his study also suggested that the IV iron sucrose tolerance seemed to be excellent without adverse side effects and was in accordance with the literature. In 2005, the FDA approved iron sucrose for the treatment of iron deficiency anemia in predialysis in chronic kidney disease (CKD) patients with or without an erythropoietin.…”

Section: Methodssupporting

confidence: 81%

Comparative Study of Intravenous Iron Sucrose Versus Oral Iron Therapy in Iron Deficiency Anemia During Postpartum Period

Kharde

Bangal

Panicker

2012

Int J of Biomed & Adv Res

View full text Add to dashboard Cite

Background:-Nutritional anemia is one of major contributory factor in high maternal mortality and morbidity in third world countries. Iron deficiency is the principle cause for nutritional anemia. The aim of the study was to compare the efficacy of oral iron therapy with intravenous iron therapy in the treatment of iron deficiency anemia during postpartum period Material and Methods:-A clinical observational study was undertaken at tertiary care teaching hospital over a period of 15 months in one hundred recently delivered women. The baseline hemoglobin and serum ferritin levels were recorded prior to treatment. After completion of the treatment the women were followed up for changes in hemoglobin and serum ferritin levels on day 5, 14 and 40. Results :-.On day 5 of the intravenous iron group , there was statistically significant increase in serum ferritin level from 11.47 +1.655 µg/l to 41.44 +6.500 µg/l (p value <0.01), and the ferritin level remained elevated on day 14 and day 40. There was significant increase in mean Hb level from 7.76+0.7137 g/dl to 10.78+0.7679 g/dl on day 40 (p value < 0.01) in oral iron group. There was increase in mean Hb level from 7.47+0.7678 g/dl to 11.41+0.7908 g/dl on day 40 in injectable iron group, which was statistically significant. (p value < 0.01) Intravenous iron sucrose did not result in any serious adverse reactions. Conclusion:-Intravenous iron sucrose administration increases the hemoglobin level and serum ferritin levels more rapidly ,without any serious adverse effect in comparison with oral ferrous sulphate in women with iron deficiency anemia in the postnatal period .

show abstract

Section: Methodssupporting

confidence: 81%

Comparative Study of Intravenous Iron Sucrose Versus Oral Iron Therapy in Iron Deficiency Anemia During Postpartum Period

Kharde

Bangal

Panicker

2012

Int J of Biomed & Adv Res

View full text Add to dashboard Cite

show abstract

“…Similar observations were reported in other studies like Prashant S. Kharde et al, Bayoumeu F et al and Khurshid Shabbir Raja et al without serious adverse effects. 15,17,18 This study is comparable with other two studies. In a study done by Agarwal Rohina S et al in 2010, showed baseline Hb 6.2g% and 5.95g%, Haematocrit 18.8 and 17.8%, MCV 71.28 and 70.1fl in IV and oral group respectively.…”

supporting

confidence: 88%

A study of efficacy and safety of intravenous iron sucrose for the treatment of moderate anaemia in antenatal women in South India

Vundi

Pudutha

Kambar

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Iron deficiency anaemia in pregnancy is a common medical problem throughout India with the burden of disease impacting on both mother and the newborn. The WHO technical group working on the prevention and treatment of anaemia has documented that parenteral iron therapy has produced a rapid and better correction of iron deficiency anaemia.Methods: A total of 61 antenatal women in the age group of 18-25yrs were enrolled and randomly assigned into study group. For a period of 4 weeks, study group received iron sucrose intravenously. The results were noted, tabulated, analysed and expressed as descriptive statistics. Student's ‘t’ test and percentages were compared using chi square test. P -value, <0.001 was considered significant. The results were analysed by using SPSS V-21 software.Results: Mean rise of Hb was 2.51±0.44 with IV iron sucrose this was highly significant (HS). Mean rise of MCV was 8.02±6.72 with IV iron sucrose this was not significant (NS). Mean rise of PCV was5.7±2.77 with IV iron sucrose. These findings showed improvement in Hb and PCV which were statistically highly significant (HS). Adverse effects were 14% in the group.Conclusions: The present study proved that iron sucrose when given intravenously there was a rapid improvement in anaemia. IV iron sucrose was proved to be safe with minimal side effects.

show abstract

“…Over the past years, various routine methods like oral iron therapy, intramuscular iron therapy, and blood transfusion were used to treat anemia during pregnancy [2]. These methods are not without deficiencies, and also there are conditions in which these conventional iron therapies are not helpful, like inadequate gastrointestinal absorption, late pregnancy, intolerance to required oral iron, requirement of emergency supplement, and severe anemia with contraindications to blood transfusion [3].…”

Section: Introductionmentioning

confidence: 99%

A Study to Compare the Efficacy and Safety of Intravenous Iron Sucrose and Intramuscular Iron Sorbitol Therapy for Anemia During Pregnancy

Singh

2012

J Obstet Gynecol India

View full text Add to dashboard Cite

Aims and Objectives To compare the efficacy, safety, and rate of response of intravenous iron sucrose and intramuscular iron sorbitol therapy for anemia during pregnancy. Material and Methods 100 antenatal cases of gestational age 14-32 weeks were included in this prospective study. Cases were randomly divided into two groups. Group A, having 50 cases received intravenous iron sucrose, and 50 cases in Group B received intramuscular iron sorbitol. Response to therapy in both groups was studied and compared. Results The mean pretherapy hemoglobin in group A was 6.49 gm/dl and in group B was 6.48 gm/dl. The rise in hemoglobin after 4 weeks of starting therapy was 3.52 gm/dl in group A and 2.33 gm/dl in group B. The difference was statistically significant (P \ 0.01). The mean time taken to achieve target hemoglobin (C11 gm/dl) was 6.37 weeks in group A and 9.04 weeks in group B. In group A, 8 % (four) cases had grade I adverse effects. In group B, 24 % (12) cases had grade I adverse effects. The difference was statistically significant (P = 0.027). In both the groups, no case discontinued the therapy. Conclusion Intravenous iron sucrose is safe, convenient, more effective, and faster acting therapy than intramuscular iron sorbitol therapy for treating moderate to severe anemia during pregnancy.

show abstract

Iron therapy in iron deficiency anemia in pregnancy: Intravenous route versus oral route

Cited by 66 publications

References 15 publications

Comparative Study of Intravenous Iron Sucrose Versus Oral Iron Therapy in Iron Deficiency Anemia During Postpartum Period

Comparative Study of Intravenous Iron Sucrose Versus Oral Iron Therapy in Iron Deficiency Anemia During Postpartum Period

A study of efficacy and safety of intravenous iron sucrose for the treatment of moderate anaemia in antenatal women in South India

A Study to Compare the Efficacy and Safety of Intravenous Iron Sucrose and Intramuscular Iron Sorbitol Therapy for Anemia During Pregnancy

Contact Info

Product

Resources

About